欢迎来到《四川大学学报（医学版）》
高级检索

SOX11、PAX5在套细胞淋巴瘤患者病理组织标本中的表达及临床意义

Relationship of Expression Between SOX11 and PAX5 in Pathological Tissue Specimens of Patients with Mantle Cell Lymphoma and Its Clinical Significance

    摘要
  • 摘要:
      目的  研究转录因子性别决定区Y框蛋白11（SRY-related HMG box 11， SOX11）、配对盒基因5（paired box domain 5， PAX5）在套细胞淋巴瘤（mantle cell lymphoma，MCL）患者病理组织标本中的表达，分析它们之间的关系及临床意义。
      方法  纳入2012年1月—2017年8月诊断的76例MCL患者为研究对象，并以56例弥漫大B细胞淋巴瘤（diffuse large B cell lymphoma，DLBCL）、38例滤泡性淋巴瘤(follicular lymphoma，FL)、9例伯基特淋巴瘤(burkitt's lymphoma，BL)患者为对照。采用实时荧光定量PCR和免疫组化法检测所有患者病理组织标本中SOX11、PAX5基因和蛋白表达水平，分析MCL患者病理组织标本SOX11与PAX5表达的相关关系，以MCL患者SOX11及PAX5蛋白表达的中位H评分为依据，将其分为高低表达组，分析SOX11及PAX5蛋白表达与临床特征及预后的关系。
      结果  SOX11、PAX5 mRNA在不同淋巴瘤组织标本中的表达差异有统计学意义（P均<0.01)，在MCL患者病理组织标本中SOX11、PAX5 mRNA表达高于其他淋巴瘤组织，两两比较，MCL与BL间差异无统计学意义(P>0.05)，与DLBCL及FL间差异有统计学意义（P均<0.01），且MCL患者病理组织标本中SOX11蛋白表达水平高于3个对照组（P均<0.000 1)，PAX5蛋白表达与对照组间差异无统计学意义(P>0.05)；在MCL患者病理组织标本中SOX11和PAX5在mRNA水平(rs=0.714, P<0.000 1)和蛋白水平(G=0.407, P=0.01)均存在正相关关系。未发现SOX11、PAX5高低表达组与MCL患者临床特征和总生存期有关。
      结论  在MCL中SOX11和PAX5表达呈正相关。单独的SOX11或PAX5表达在MCL患者预后分层中的作用不显著。

     

    Abstract:
      Objective  Investigate the expression of SRY-related HMG box 11 (SOX11) and paired box domain 5 (PAX5) in patients with mantle cell lymphoma (MCL) and analyze the relationship between them and their clinical significance.
      Methods  Seventy-six formalin-fixed paraffin-embedded (FFPE) samples of patients who were diagnosed with MCL from January 2012 to August 2017 were collected．Fifty-six FFPE samples from patients with diffuse large B cell lymphoma (DLBCL), thirty-eight FFPE samples from patients with follicular lymphoma (FL) and nine FFPE samples from patients with Burkitt's lymphoma (BL) were used as control groups. Real-time quantitative PCR (qRT-PCR) and immunohistochemistry were used to detect the mRNA and protein expressions of SOX11 and PAX5. The association between expressions of SOX11 and PAX5 in patients with MCL was analyzed. On the basis of the median H score of SOX11 and PAX5 protein expressions in patients with MCL, they were divided into high and low expression group, and the relationship between the different groups and patients’ clinical characteristics and prognosis were analyzed.
      Results  The different mRNA expression levels of SOX11 and PAX5 in different lymphoma tissues were statistically significant (P<0.01). The mRNA expression levels of SOX11 and PAX5 in MCL group were higher than those of the control groups, and the differences of those between MCL and DLBCL or FL were statistically significant (P<0.01). However, the differences of those between MCL and BL were not significant (P>0.05). The expression level of SOX11 protein was also higher than those of the control groups (P<0.000 1). However, there was no significant difference in PAX5 protein expression level between the MCL group and the control group, nor the expression levels of SOX11 and PAX5 genes and proteins among the control groups (P>0.05). By analyzing the samples from patients with MCL, we observed a positive relevance between SOX11 and PAX5 both in mRNA expression level (rs=0.714, P<0.000 1) and protein expression level (G=0.407, P=0.01). There was no difference in clinical characteristics and overall survival between the high and low expression group.
      Conclusion  In MCL, there was a positive relevance between the expressions of SOX11 and PAX5. The expression of SOX11 or PAX5 alone has no significant effect on the prognostic stratification of MCL patients.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回